Clinical study "SWIFT": Influence of blood coagulation factor 13 on heavy bleeding after childbirth

As part of a research project at the University Hospital Zurich, a link between a blood coagulation factor (factor 13) and postnatal blood loss has been established in recent years. This study, which is being conducted at several university hospitals and hospitals in Switzerland, aims to confirm the effect of this coagulation factor in almost 1,000 patients. Coagulation factor 13 is an authorised treatment.

Principal investigator / Sponsor

Prof. Dr Christian Haslinger, Head Physician, Department of Obstetrics, University Hospital Zurich

Local investigator

Dr Michael Winter, Senior Physician, Women's Clinic, Zollikerberg Hospital

Who can take part in this study?

Pregnant women aged 18 and over who are due to give birth at Zollikerberg Hospital. Women with a planned caesarean section, multiple pregnancies or known coagulation disorders are excluded from the study.

Procedure and duration of the study

You will be included in the study if you have heavy bleeding immediately after the birth. In this case, you will be randomly assigned to either the study group (standard treatment plus short infusion of coagulation factor 13) or the control group (standard treatment only).

In the event of severe postpartum haemorrhage, we will measure the blood loss and compare it in both groups. We will also examine and question you on the day after the haemorrhage and when you are discharged from hospital. Six to nine weeks after the birth, we will also ask you about your state of health by telephone.

Compensation for expenses

None.

All data will be treated confidentially. Participation is voluntary. If you are interested in participating in the study, please contact us. Your data will be registered. If you do not participate, your data will be deleted immediately.

Consent / Information German

Size

234.2 KiB